

FRIDAY, DECEMBER 9 - SUNDAY, DECEMBER 11 New York Hilton Midtown



FRI	DAY	/. DI	ECE	MB	ER 9

7:45 - 8 a.m. Welcome

Valentin Fuster, MD, PhD, MACC

Course Director New York, NY

Edward T.A. Fry, MD, FACC

President, American College of Cardiology

Indianapolis, IN

Cardiovascular and Coronary Artery Disease — Challenges in 2022

Session I: Evolving New Frontiers of Imaging Ready for Practice

Chair: Edward T.A. Fry, MD, FACC

8 - 8:25 a.m.	Evolving Approaches for Primordial, Primary, and Secondary Prevention: Very Early Education, Non-Invasive CV/Brain Imaging, and Polypill Respectively Valentin Fuster, MD, PhD, MACC New York, NY
8:25 - 8:45 a.m.	Evolving Imaging Approaches for a Full Evaluation of Coronary Disease: CTA Anatomy, Plaque Structure, and Functional Characteristics Ron Blankstein, MD, FACC Boston, MA
8:45 – 9:05 a.m.	Evolving Tools Targeting and Interpreting Vasomotion Dependent Ischemia: Epicardial, Microvasculature, Takotsubo Syndromes, and Other Tricks Yuhei Kobayashi, MD New York, NY
9:05 - 9:25 a.m.	Panel Discussion Drs. Blankstein, Fry, Fuster, and Kobayashi
9:25 - 9:45 a.m.	Break
Session II: Acute Coro	nary Syndrome Advances

Chair: Roxana Mehran, MD, FACC

onani nonana moman, m		
9:45 - 10:05 a.m.	Evolving Strategies for Acute Coronary Syndromes: Differences Between US and European Clinical Practice Guidelines Borja Ibanez, MD Madrid, Spain	
10:05 - 10:25 a.m.	Evolving Three Strategies of Platelet Inhibitors in Coronary Disease: Chronic Native Disease, 1 to 6 Months Post PCI, and Long-Term Post PCI Roxana Mehran, MD, FACC New York NY	





Friday, December 9 (co	ntinued)
10:25 - 10:45 a.m.	Evolving Two Strategies of New Oral Anticoagulants in Coronary Disease: Post-MI Left Ventricular Dysfunction and Chronic Native Disease Deepak L. Bhatt, MD, MPH, FACC Boston, MA
10:45 - 11:05 a.m.	Evolving Subacute and Chronic Impact of COVID-19 on Cardiovascular Sequelae: Autonomic Nervous System Dysfunction (ANSD) as a Primary Concern Joseph Parrillo, MD, FACC Hackensack, NJ
11:05 - 11.30 a.m.	Panel Discussion Drs. Bhatt, Ibanez, Mehran, and Parrillo
11.30 a.m 1 p.m.	Lunch
Session III: Chronic Con Chair: Judith S. Hochman,	ronary Disease, Stroke, and Pulmonary Embolism MD, FACC
1 - 1:25 p.m.	Evolution in the Management of Stable Coronary MVD: CABG, PCI, CABG Versus PCI, OMT, and Microvasculature Valentin Fuster, MD, PhD, MACC New York, NY
1:25 – 1:45 p.m.	Evolving New Challenges as a Result of the ISCHEMIA Trial — ISCHEMIA EXTEND Interim Results: Quality of Life? Adherence to OMT? Predictions at 10 Years? Judith S. Hochman, MD, FACC New York, NY
1:45 - 2:05 p.m.	Evolving Strategies for Carotid Disease, Ischemic, and Hemorrhagic Stroke: Differences Between US and European Clinical Practice Guidelines Joshua Z. Willey, MD New York, NY
2:05 - 2:25 p.m.	Evolving Advances in DVT and Pulmonary Emboli: Evaluation, Prevention, and Management Gregory Piazza, MD, FACC Boston, MA
2:25 - 2:45 p.m.	Panel Discussion Drs. Fuster, Hochman, Piazza, and Willey
2:45 – 3 p.m.	Break
Session IV: Trends and Chair: Pamela Bowe Morris	Challenges of Approaching Prevention — Health Factors s, MD, FACC
3 - 3:20 p.m.	The Good News — Cardiorespiratory Fitness, Peak 02/MET's, and Survival: Physical Activity as the Best Investment in Preventive CV Medicine Carl J. Lavie, MD, FACC New Orleans, LA



FRIDAY, DECEMBER 9 - SUNDAY, DECEMBER 11 New York Hilton Midtown



3:20 - 3:40 p.m.	The Bad News — Cardiovascular Disease Projections in the US:	
	An Alarming Situation for the Cardiovascular Community	
	Andreas P. Kalogeropoulos, MD, MPH, PhD, FACC	
	Stony Brook, NY	
3:40 – 4 p.m.	Obesity as a Huge Epidemiological Challenge:	
	From Genetics and Behavior to Pharmacotherapy and Bariatric Surgery	
	W. Timothy Garvey, MD	
	Birmingham, AL	
4 – 4:20 p.m.	Lipid-Modifying Agents as a Continuous Success Development:	
	From Statins to PCSK9 Inhibitors and Beyond	
	Pamela Bowe Morris, MD, FACC	
	Charleston, SC	
4:20 – 4:40 p.m.	Diabetic-Modifying Agents in Evolution:	
	From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists	
	David Preiss, MD, PhD Oxford, United Kingdom	
4.40 Enm		
4:40 – 5 p.m.	Hypertension as Number One Killer of CVD Seems to Be Neglected: An Obsession on BP Levels, but Not in Identifying and Following the Affected	
	Franz H. Messerli, MD, FACC	
	Bern, Switzerland	
5 p.m.	Adjournment	

SATURDAY, DECEMBER 10

Cardio-Pulmonary and Electrical Failure 2022

Session V: Myocardial Disease and Heart Failure — Basis for Management

Chair: Maria Rosa Costanzo, MD, FACC

8 - 8:25 a.m.	Evolving Imaging (MRI, PET) for Seven Myocardial Diseases: Myocarditis, DCM, HCM, NCLV, Amyloid CM, Sarcoid, and Takotsubo — Diagnostic and Prognostic Tools Y.S. Chandrashekhar, MD, FACC Minneapolis, MN
8:25 - 8:45 a.m.	Evolving Pharmacology for Heart Failure: Approach to Clinical Trials and Practice Christopher O'Connor, MD, MACC Falls Church, VA
8:45 – 9:05 a.m.	Evolving Understanding of HFrEF Versus HFiEF Versus HFpEF Phenotypes: Therapeutic Role of ARNIs and SGLT2 Inhibitors in the Three Entities Maria Rosa Costanzo, MD, FACC Wheaton, IL





Saturday, December 10 (c	onunuea)
9:05 – 9:25 a.m.	Evolving Therapeutic Approaches to Four Challenging Cardiomyopathies: Myocarditis and COVID 19, Takotsubo, AL/TTR Amyloid, and NCLV Mathew S. Maurer, MD, FACC New York, NY
9:25 - 9:45 a.m.	Assist Devices in Cardiac Decompensation — The Two Challenges: 1. LVAD Indications: Not Too Early Since Risks Are High, but Not Late 2. Assist Devices in the Acute Decompensation: Impella Versus ECMO Biykem Bozkurt MD, PhD, FACC Houston, TX
9:45 - 10:15 a.m.	Panel Discussion Drs. Bozkurt, Costanzo Chandrashekhar, O'Connor, and Maurer
10:15 - 10:30 a.m.	Break
Session VI: Rhythm Disord	ders, Contemporary and Future Topics of Focus
Chair: Francis E. Marchlinski,	MD, FACC
10:30 - 10:55 a.m.	Atrial Fibrillation — Evolving Clinical Challenges: Quality of Life and Preventing Stroke Valentin Fuster, MD, PhD, MACC New York, NY
10:55 - 11:15 a.m.	Atrial Fibrillation — Evolving Ablation Tools and LAA Closure: Who? When? How? Long-Term Results? Vivek Y. Reddy, MD, FACC New York, NY
11:15 - 11:30 a.m.	Sinus Tachycardia — Inappropriate Type, Role of Ivabradine: Who? When? How? Long-Term Results? Dhanunjaya R. Lakkireddy, MBBS, FACC Overland Park, KS
11:30 a.m 11:50 a.m.	Ventricular Tachycardia — Catheter Ablation: Who? When? How? Long-Term Results? Francis E. Marchlinski, MD, FACC Philadelphia, PA
11:50 a.m 12:10 p.m.	Three Device Therapeutic Approaches — CRTs Strict Indications, Subcutaneous ICDs, and Leadless Pacemakers: Who? When? How? Long-Term Results? Michael Robert Gold, MD, PhD, FACC Charleston, SC
12:10 - 12:30 p.m.	Panel Discussion Drs. Fuster, Gold, Lakkireddy, Marchlinski, and Reddy
12:30 – 2 p.m.	Lunch





Saturday, December 10 (continued)	
	and Aorta — Challenges in 2022 ent of Aortic Valve Disease and Aorta MD, MACC
2 – 2:20 p.m.	The Ten Major Advances in Structural Heart Disease in 2021-2022 Samin K. Sharma, MBBS, FACC New York, NY
2:20 – 2:35 p.m.	Aortic Valvular Stenosis — Three Diagnostic and Management Challenges: 1. Congenital Bicuspid Versus Senile 2. Asymptomatic Versus Symptomatic 3. Low Flow/Low Gradient: CM Secondary to AS Versus Dilated or Restrictive Robert O. Bonow, MD, MACC Chicago, IL
2:35 - 2:45 p.m.	Critical Commentary: Drs. Adams, Rodés-Cabau, Sharma, and Stone
2:45 – 3 p.m.	Aortic Regurgitation — 3 Diagnostic and Management Challenges: 1. Associated or Not Dilatation of the Aorta 2. Asymptomatic Versus Symptomatic 3. EF Low/Intermediate Versus Normal Robert O. Bonow, MD, MACC Chicago, IL
3 – 3:10 p.m.	Critical Commentary: Drs. Adams, Rodés-Cabau, Ommen, Sharma and Stone
3:10 - 3:25 p.m.	The Dilated Thoracic and Abdominal Aorta, and Complicating Dissection: Evolving Understanding of the Basic Biology and Management Valentin Fuster, MD, PhD, MACC New York, NY
3:25 – 3:35 p.m.	Critical Commentary: Dr. El-Hamamsy
3:35 – 3:50 p.m.	Break
Session VIII: Managem Chair: David H. Adams, M	nent of Mitral Regurgitation, Tricuspid Regurgitation, and Hypertrophic Cardiomyopathy D, FACC
3:50 - 4:05 p.m.	Mitral Regurgitation — Three Diagnostic and Management Challenges: 1. Primary Versus Secondary 2. Asymptomatic Versus Symptomatic 3. EF Low/Intermediate Versus Normal Gregg W. Stone, MD, FACC New York, NY
4:05 – 4:15 p.m.	Critical Commentary: Drs. Adams, Bonow, Rodés-Cabau, Ommen, and Sharma



FRIDAY, DECEMBER 9 - SUNDAY, DECEMBER 11 New York Hilton Midtown



Saturday, December 10 (continued)	
4:15 – 4:30 p.m.	Tricuspid Regurgitation — Three Diagnostic and Management Challenges: 1. Primary Versus Secondary to Pulmonary Hypertension 2. Residual From Previous Left Sided Valvular Surgery or Not 3. Symptomatic With RVEF Low/Intermediate Versus Normal Josep Rodés-Cabau, MD Quebec, Canada
4:30 – 4:40 p.m.	Critical Commentary: Drs. Adams, Bonow, Ommen, Stone, and Sharma
4:40 – 5 p.m.	Hypertrophic Cardiomyopathy — Five Challenging Questions: Genetic/Acquired, Mavacamtem, Myectomy, Apical, and Sudden Death Steve R. Ommen, MD, FACC Rochester, MN
5 p.m.	Adjournment

SUNDAY, DECEMBER 11

Year In Review: 10 Highlights of Progress in 2022

Session IX: Novelties on Pharmacology, Clinical and Epidemiological CV Science

Chair: Valentin Fuster, MD, PhD, MACC

8 - 8:20 a.m.	Lipoprotein (a) With Atherosclerotic Plaque Risk and Effect of "Pelacarsen" Sotirios Tsimikas, MD, FACC La Jolla, CA
8:20 - 8:40 a.m.	Evolving Pharmacological Spectrum of the "Polypill" for Secondary Prevention Jose M. Castellano, PhD Madrid, Spain
8:40 - 9 a.m.	"Immune Checkpoint" Therapies: Myocardial and Coronary Side Effects Bonnie Ky, MD, FACC Philadelphia, PA
9 - 9:20 a.m.	Post-MI Mitral Valve Remodeling and Effect of "Cyproheptadine" Ons Marsit, MSc Quebec, Canada
9:20 – 9:40 a.m.	In AF, Restoring SR Reverses Heart Remodeling and Valvular Regurgitation Laurie Soulat-Dufour, MD Paris, France
9:40 – 10 a.m.	Advances in Primary Pulmonary Hypertension Vallerie V. McLaughlin, MD, FACC Ann Arbor, MI
10 - 10.20 a.m.	Evolving Clinical Genetics and Omics in Seven Myocardial Diseases: Which Subgroup or When Should Be Gene Tested? Amy Kontorovich, MD, FACC New York, NY





Sunday, December 11 (continued)	
10:20 - 10:40 a.m.	Myocardial Fibrosis Predictive of Ventricular Arrhythmias and Sudden Death Christopher M. Kramer, MD Charlottesville, VA
10:40 - 11 a.m.	Transcatheter Intervention in CHD: Septal Defects and Valve Dysfunction Mariel Turner, MD, FACC New York, New York
11 - 11:30 a.m.	Epicardial Fat Inflammatory Signaling in Atrial Fibrillation, Coronary Artery Disease and Heart Failure Gianluca lacobellis, MD Miami, FL
11:30 a.m.	Adjourn